Core Insights - IDEAYA Biosciences announced the publication of abstracts for presentations on IDE275 (GSK959) at the AACR Annual Meeting, highlighting its potential as a best-in-class Werner Helicase inhibitor for treating high microsatellite instability (MSI-H) solid tumors [1][2][3] Company Overview - IDEAYA Biosciences is focused on precision medicine in oncology, developing targeted therapeutics based on molecular diagnostics [9] - The company collaborates with GSK, which is responsible for 80% of the global research and development costs for IDE275 (GSK959) [4] Product Development - IDE275 (GSK959) has shown selective preclinical efficacy in MSI-H solid tumors, with significant prevalence rates of approximately 31% in endometrial, 20% in colorectal, and 19% in gastric cancers [3][7] - The drug is currently in a Phase 1 dose escalation trial in partnership with GSK, with the potential for further clinical development as both a monotherapy and in combination with PD1 inhibitors [2][7] Financial Aspects - IDEAYA could earn a $10 million milestone payment upon the initiation of Phase 1 clinical dose expansion and is eligible for up to $465 million in future milestone payments [4] - Upon commercialization, IDEAYA stands to receive up to $475 million in commercial milestones, 50% of U.S. net profits, and tiered royalties on global non-U.S. net sales of IDE275 [4] Upcoming Presentations - At the AACR 2025, IDEAYA will present a total of 8 presentations across various programs, including 4 focused on IDE275 (GSK959) [5][7]

Core Insights - IDEAYA Biosciences has announced a research collaboration with ATTMOS to develop a physics-based computational small molecule discovery platform targeting undruggable oncology targets [1][2] - The partnership aims to integrate IDEAYA's structural biology and drug discovery capabilities with ATTMOS's computational chemistry and software development expertise [2][3] - The collaboration will utilize the Amber molecular dynamics suite for free energy simulations and aims to enhance the efficiency of drug discovery for novel oncology therapeutics [4] Company Overview - IDEAYA Biosciences focuses on precision medicine in oncology, developing targeted therapeutics based on molecular diagnostics [5] - The company is committed to identifying and validating translational biomarkers to select patient populations that will benefit from its therapies [5] ATTMOS Overview - ATTMOS was founded in early 2022 by a team of academics from Michigan State, Rutgers, and UC San Diego [6] - The company's mission is to integrate novel technologies into the drug discovery process, making them affordable and accessible [6]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38915 IDEAYA Biosciences, Inc. (Exact name of Registrant as specified in its Charter) Delaware 47-4268251 (State or other jurisdictio ...

Core Viewpoint - IDEAYA Biosciences, Inc. (IDYA) has experienced significant selling pressure, resulting in an 8.6% decline in stock price over the past four weeks, but analysts anticipate improved earnings in the near future [1] Group 1: Stock Performance and Technical Indicators - IDYA's stock is currently in oversold territory, indicated by a Relative Strength Index (RSI) reading of 29.84, suggesting a potential trend reversal [5] - The RSI is a momentum oscillator that helps identify whether a stock is oversold, typically when the reading falls below 30 [2][3] Group 2: Earnings Estimates and Analyst Sentiment - Over the last 30 days, the consensus EPS estimate for IDYA has increased by 1.3%, reflecting a positive trend in earnings estimate revisions [6] - A Zacks Rank of 2 (Buy) places IDYA in the top 20% of over 4,000 ranked stocks, indicating strong potential for a turnaround based on earnings estimate trends [7]

IDEAYA Biosciences, Inc. (IDYA) came out with a quarterly loss of $1.49 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.52 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -122.39%. A quarter ago, it was expected that this company would post a loss of $0.67 per share when it actually produced a loss of $0.60, delivering a surprise of 10.45%.Over the last four quarters, the company h ...

Financial Performance - As of December 31, 2024, IDEAYA had approximately $1.1 billion in cash, cash equivalents, and marketable securities, up from $632.6 million as of December 31, 2023, primarily due to $379.9 million in net proceeds from common stock sales[11]. - The net loss for Q4 2024 was $130.3 million, compared to a net loss of $34.0 million in Q4 2023, with total stock compensation expense rising to $9.5 million from $4.8 million[16]. - For the full year 2024, the net loss was $274.5 million, compared to $113.0 million in 2023, with total stock compensation expense increasing to $34.7 million from $18.5 million[17]. - Total operating expenses for Q4 2024 were $151,138,000, up from $45,838,000 in Q4 2023, indicating a significant increase of approximately 229.5%[23]. - Net loss for Q4 2024 was $130,312,000, compared to a net loss of $33,955,000 in Q4 2023, reflecting an increase in losses of approximately 284.5%[23]. - The comprehensive loss for Q4 2024 was $133,336,000, compared to $32,643,000 in Q4 2023, representing an increase of approximately 308%[23]. - Total assets increased to $1,124,091,000 in 2024 from $649,316,000 in 2023, representing a growth of approximately 73%[25]. Revenue and Collaboration - Collaboration revenue for Q4 2024 totaled $7.0 million, compared to $3.9 million in Q4 2023, driven by a $7.0 million milestone payment from GSK for IND clearance of IDE275[13]. - Collaboration revenue for Q4 2024 was $7,000,000, compared to $3,923,000 in Q4 2023, representing an increase of approximately 78.5%[23]. Research and Development - Research and development expenses for Q4 2024 were $140.2 million, significantly higher than $38.8 million in Q4 2023, mainly due to a $75.0 million upfront payment for IDE849 and increased clinical trial costs[14]. - Research and development expenses for the year ended December 31, 2024, were $294,673,000, compared to $129,508,000 in 2023, marking an increase of approximately 128%[23]. - General and administrative expenses for the year ended December 31, 2024, were $39,302,000, up from $28,306,000 in 2023, indicating an increase of approximately 39%[23]. - Over 230 patients have been enrolled in the potential registration-enabling trial for 1L HLA-A2-negative MUM, with a median PFS readout targeted by year-end 2025[4]. - IDEAYA plans to initiate a Phase 3 registration-enabling trial for darovasertib in neoadjuvant UM in the first half of 2025, with 95 patients already enrolled[6]. - The company is targeting clinical data updates for IDE397 in combination with Trodelvy in MTAP-deletion UC in 2025, following encouraging Phase 1 results presented at ENA 2024[7]. - IDEAYA aims to submit a U.S. IND for IDE849 as a monotherapy in SCLC in the first half of 2025, with preliminary results showing an overall response rate of approximately 73% in a Phase 1 trial[7]. - The company anticipates filing INDs for three new candidates: IDE892 (PRMT5) in mid-2025, IDE034 (B7H3/PTK7 ADC) in the second half of 2025, and IDE251 (KAT6/7) also in the second half of 2025[9]. Shareholder Information - The weighted-average number of shares outstanding increased to 87,340,758 in Q4 2024 from 65,246,361 in Q4 2023, reflecting an increase of approximately 33.9%[23]. Future Outlook - IDEAYA is focused on advancing its clinical programs and expects to provide updates on regulatory milestones and trial data in the near future[20].

Core Insights - IDEAYA Biosciences, Inc. reported financial results for Q4 and the full year ended December 31, 2024, highlighting significant advancements in its clinical pipeline and financial position [1][9]. Financial Performance - As of December 31, 2024, IDEAYA had approximately $1.1 billion in cash, cash equivalents, and marketable securities, an increase from $632.6 million as of December 31, 2023, primarily due to $379.9 million in net proceeds from common stock sales and $283.8 million from an underwritten public offering [9]. - Collaboration revenue for Q4 2024 was $7.0 million, up from $3.9 million in Q4 2023, driven by a milestone payment from GSK for IND clearance of IDE275 [11]. - Research and development expenses for Q4 2024 totaled $140.2 million, significantly higher than $38.8 million in Q4 2023, mainly due to a $75.0 million upfront payment for IDE849 and increased clinical trial expenses [12]. - The net loss for Q4 2024 was $130.3 million, compared to a net loss of $34.0 million in Q4 2023 [13]. Clinical Pipeline Updates - The company is targeting multiple clinical data readouts in 2025, including updates on darovasertib for neoadjuvant UM and IDE275 at major medical conferences [2][3]. - Over 230 patients have been enrolled in a registration-enabling trial for darovasertib in 1L HLA-A2-negative MUM, with a median PFS readout expected by year-end 2025 [5][7]. - IDEAYA plans to advance its IDE397 and IDE892 combination into clinical trials in the second half of 2025, following promising results in MTAP-deletion cancers [3][5]. - The company has made significant progress with the in-licensing of IDE849 and received FDA clearance for the Phase 1 trial of IDE275, with updates expected in 2025 [3][5]. Corporate Developments - IDEAYA appointed Joshua Bleharski as Chief Financial Officer and Stu Dorman as Chief Commercial Officer, both bringing extensive experience in the biopharmaceutical sector [14]. - The company is advancing three programs into IND-enabling studies, targeting IND filings for IDE892, IDE034, and IDE251 in the second half of 2025 [5][14].

Core Insights - IDEAYA Biosciences has entered into a clinical study collaboration and supply agreement with Gilead Sciences to evaluate the efficacy and safety of IDE397, a potential first-in-class MAT2A inhibitor, in combination with Gilead's Trodelvy in MTAP-deletion non-small cell lung cancer (NSCLC) [1][10] - The combination aims to target two distinct and complementary mechanisms related to MTAP-deletion in solid tumors [10] Company Overview - IDEAYA Biosciences is focused on precision medicine in oncology, developing targeted therapeutics based on molecular diagnostics [8] - The company integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its therapies [8] Clinical Development - IDE397 is a selective small molecule inhibitor targeting methionine adenosyltransferase 2a (MAT2A), with an estimated prevalence of MTAP-deletion at approximately 15% in NSCLC, translating to around 48,000 cases annually in the U.S. [3][10] - The ongoing Phase 1 trial is expanding to include patients with MTAP-deletion NSCLC, in addition to those with MTAP-deletion urothelial cancer [2][5] Trodelvy Overview - Trodelvy is currently approved in over 50 countries for second-line or later metastatic triple-negative breast cancer (TNBC) and in more than 40 countries for certain pre-treated HR+/HER2-metastatic breast cancer patients [4]

Company Overview - Ideaya Biosciences, Inc. (NASDAQ: IDYA) is making significant progress with its pipeline, particularly with its lead candidate darovasertib, which is currently in a potential ongoing phase 2/3 study [2] Investment Analysis - The Biotech Analysis Central service offers a comprehensive analysis of various pharmaceutical companies, including a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [2]

IDEAYA Biosciences, Inc. (IDYA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the s ...